Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: Focus on RHO GTPase-regulated gene transcription

Pei Suen Tsou, Andrew J. Haak, Dinesh Khanna, Richard R. Neubig

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Tissue fibrosis occurs with excessive extracellular matrix deposition from myofibroblasts, resulting in tissue scarring and inflammation. It is driven by multiple mediators, such as the G protein-coupled receptor ligands lysophosphatidic acid and endothelin, as well as signaling by transforming growth factor-β, connective tissue growth factor, and integrins. Fibrosis contributes to 45% of deaths in the developed world. As current therapeutic options for tissue fibrosis are limited and organ transplantation is the only effective treatment for end-stage disease, there is an imminent need for efficacious antifibrotic therapies. This review discusses the various molecular pathways involved in fibrosis. It highlights the Rho GTPase signaling pathway and its downstream gene transcription output through myocardin-related transcription factor and serum response factor as a convergence point for targeting this complex set of diseases.

Original languageEnglish (US)
Pages (from-to)C2-C13
JournalAmerican Journal of Physiology - Cell Physiology
Volume307
Issue number1
DOIs
StatePublished - Jul 1 2014

Keywords

  • Drug development
  • Fibrosis
  • Gene transcription
  • Rho GTPase
  • Therapeutics

ASJC Scopus subject areas

  • Physiology
  • Cell Biology

Fingerprint Dive into the research topics of 'Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: Focus on RHO GTPase-regulated gene transcription'. Together they form a unique fingerprint.

Cite this